CTKB vs. LAB, QTRX, EYPT, VALN, PACB, ALLO, PRTA, NAUT, MYGN, and OLK
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include Standard BioTools (LAB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Valneva (VALN), Pacific Biosciences of California (PACB), Allogene Therapeutics (ALLO), Prothena (PRTA), Nautilus Biotechnology (NAUT), Myriad Genetics (MYGN), and Olink Holding AB (publ) (OLK). These companies are all part of the "medical" sector.
Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cytek Biosciences had 6 more articles in the media than Standard BioTools. MarketBeat recorded 12 mentions for Cytek Biosciences and 6 mentions for Standard BioTools. Cytek Biosciences' average media sentiment score of 0.05 beat Standard BioTools' score of -0.19 indicating that Cytek Biosciences is being referred to more favorably in the media.
Cytek Biosciences currently has a consensus target price of $8.63, suggesting a potential upside of 37.34%. Standard BioTools has a consensus target price of $3.58, suggesting a potential upside of 41.63%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Cytek Biosciences.
Cytek Biosciences received 15 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 42.86% of users gave Cytek Biosciences an outperform vote.
Cytek Biosciences has a net margin of -5.73% compared to Standard BioTools' net margin of -70.98%. Cytek Biosciences' return on equity of -1.78% beat Standard BioTools' return on equity.
69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 15.9% of Cytek Biosciences shares are owned by company insiders. Comparatively, 53.1% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Cytek Biosciences has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.
Summary
Cytek Biosciences beats Standard BioTools on 10 of the 17 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
